Literature DB >> 1605615

Effect of cyclodextrin on the pharmacology of antifungal oral azoles.

J S Hostetler1, L H Hanson, D A Stevens.   

Abstract

Concentrations of oral azoles in serum were compared in a single-dose pharmacologic study in mice. When hydroxypropyl-beta-cyclodextrin was used as a carrier and compared with a standard carrier, polyethylene glycol, drug concentrations determined by bioassay showed that the peak concentration and area under the concentration-time curve were greatly enhanced for itraconazole and saperconazole; moderately enhanced for ketoconazole; but negligibly affected for fluconazole, miconazole, and SCH 42427.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1605615      PMCID： PMC188462          DOI： 10.1128/AAC.36.2.477

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Increased gastric pH and the bioavailability of fluconazole and ketoconazole.

Authors:  R A Blum; D T D'Andrea; B M Florentino; J H Wilton; D M Hilligoss; M J Gardner; E B Henry; H Goldstein; J J Schentag
Journal:  Ann Intern Med       Date:  1991-05-01       Impact factor: 25.391

2.  Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography.

Authors:  J H Rex; L H Hanson; M A Amantea; D A Stevens; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

3.  Pharmacology and toxicity of high-dose ketoconazole.

Authors:  A M Sugar; S G Alsip; J N Galgiani; J R Graybill; W E Dismukes; G A Cloud; P C Craven; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

4.  The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection.

Authors:  J M Wishart
Journal:  J Am Acad Dermatol       Date:  1987-08       Impact factor: 11.527

5.  Treatment of paracoccidioidomycosis with itraconazole in a murine model.

Authors:  J G McEwen; G R Peters; T F Blaschke; E Brummer; A M Perlman; A Restrepo; D A Stevens
Journal:  J Trop Med Hyg       Date:  1985-10

6.  Treatment of invasive aspergillosis with itraconazole.

Authors:  D W Denning; R M Tucker; L H Hanson; D A Stevens
Journal:  Am J Med       Date:  1989-06       Impact factor: 4.965

Review 7.  Cyclodextrins in drug carrier systems.

Authors:  K Uekama; M Otagiri
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1987       Impact factor: 4.889

8.  Disposition of ketoconazole, an oral antifungal, in humans.

Authors:  C Brass; J N Galgiani; T F Blaschke; R Defelice; R A O'Reilly; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191
  8 in total
  29 in total

1.  Efficacy of micafungin alone or in combination against systemic murine aspergillosis.

Authors:  Javier Capilla Luque; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 2.  Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.

Authors:  K N Sorensen; K V Clemons; D A Stevens
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

3.  Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs.

Authors:  Karl V Clemons; Gloria M Gonzalez; Gaurav Singh; Jackie Imai; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

4.  Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.

Authors:  J A Barone; B L Moskovitz; J Guarnieri; A E Hassell; J L Colaizzi; R H Bierman; L Jessen
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

5.  Systemic availability of itraconazole in lung transplantation.

Authors:  T F Patterson; J Peters; S M Levine; A Anzueto; C L Bryan; E Y Sako; O L Miller; J H Calhoon; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

6.  Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.

Authors:  James Kim; Jean Y Tang; Ruoyu Gong; Jynho Kim; John J Lee; Karl V Clemons; Curtis R Chong; Kris S Chang; Mark Fereshteh; Dale Gardner; Tannishtha Reya; Jun O Liu; Ervin H Epstein; David A Stevens; Philip A Beachy
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

7.  Efficacy of posaconazole in a murine model of central nervous system aspergillosis.

Authors:  Jackie K Imai; Gaurav Singh; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis.

Authors:  H M Miyazaki; S Kohno; Y Miyazaki; K Mitsutake; K Tomono; M Kaku; H Koga; K Hara
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

9.  Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B.

Authors:  A M Sugar; M Salibian; L Z Goldani
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

10.  Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.

Authors:  J Berenguer; N M Ali; M C Allende; J Lee; K Garrett; S Battaglia; S C Piscitelli; M G Rinaldi; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.